Product Overview
                                                                    
                                                                
                                                                As a therapeutic tool, macrophage cell has a great capacity for delivering cargos because of their intrinsic characteristics. This product is engineered Mouse Bone Marrow-derived Hematopoietic Stem/Progenitor Cells (HSPCs) carried with Chemo drugs by Nanoparticle System-Oligomannose-coated liposome. MacroCargo™ products aim to improve the macrophage function and delivery of specific cargos. We also provide custom macrophage delivery systems based on your specific requirements.
                                                             
                                                            
                                                                
                                                                    
                                                                        Cell Name
                                                                    
                                                                
                                                                Bone Marrow-derived Hematopoietic Stem/Progenitor Cells (HSPCs)
                                                             
                                                            
                                                            
                                                            
                                                                
                                                                    
                                                                        Cell Background
                                                                    
                                                                
                                                                High-dose chemotherapy followed by adjuvant autologous hematopoietic stem/progenitor cell (HSPC) transplantation has been tested for the treatment of hematological and solid tumors and can be regarded as a clinical option for certain types of cancer. Scientists have highlighted the important contribution of bone marrow (BM)-derived myeloid cells to tumor angiogenesis.